ClinicalTrials.gg
RecruitingNCT05318599DeepBreathUpdated Apr 12, 2024

Deep Learning Diagnostic and Risk-stratification for IPF and COPD

An observational study in Lung; Disease, Interstitial, With Fibrosis, Pulmonary Disease, Chronic Obstructive and Artificial Intelligence, sponsored by Pediatric Clinical Research Platform. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.

Primary conditionPulmonary Disease, Chronic ObstructiveRegistry: DiseaseReclassifiedWhy we changed it
Registry
Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Disease, Chronic Obstructive
Why
  1. Disease describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Pulmonary Disease, Chronic Obstructive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pediatric Clinical Research Platform · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland — 15 open to participants now, 20 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Switzerland.

Planned enrollment
11th of 22
160 · median 128
Started
2023
with 5 others
Observational
22 of 99
5 open now
Primary completion
2024-10
later than 1 of 19 live
Registered
76th of 99
by date

Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, this one is the 11th largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2023, is one of 22 observational ones, reaches primary completion later than 1 of the 19 other live ones, and was the 76th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

15 of the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, or all of them as a file.
02

Study summary

Idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and chronic obstructive pulmonary disease (COPD) are severe, progressive, irreversibly incapacitating pulmonary disorders with modest response to therapeutic interventions and poor prognosis. Prompt and accurate diagnosis is important to enable patients to receive appropriate care at the earliest possible stage to delay disease progression and prolong survival.

Artificial intelligence (AI)-assisted digital lung auscultation could constitute an alternative to conventional subjective operator-related auscultation to accurately and earlier diagnose these diseases. Moreover, lung ultrasound (LUS), a relevant gold standard for lung pathology, could also benefit from automation by deep learning.

Read the detailed description

Aim: To develop and determine the predictive power of an AI (deep learning) algorithm in identifying the acoustic and LUS signatures of IPF, NSIP and COPD in an adult population and discriminating them from age-matched, never smoker, control subjects with normal lung function.

Methodology: A single-center, prospective, population-based case-control study that will be carried out in subjects with IPF, NSIP and COPD. A total of 120 consecutive patients aged ≥ 18 years and meeting IPF, NSIP or COPD international criteria, and 40 age-matched controls, will be recruited in a Swiss pulmonology outpatient clinic with a total of approximately 7000 specialized consultations per year, starting from August 2022.

At inclusion, demographic and clinical data will be collected. Additionally, lung auscultation will be recorded with a digital stethoscope and LUS performed. A deep learning algorithm (DeepBreath) using various deep learning networks with aggregation strategies will be trained on these audio recordings and lung images to derive an automated prediction of diagnostic (i.e., positive vs negative) and risk stratification categories (mild to severe).

Secondary outcomes will be to measures the association of analysed lung sounds with clinical, functional and radiological characteristics of IPF, NSIP and COPD diagnosis. Patients' quality of life will be measured with the standardized dedicated King's Brief Interstitial Lung Disease (K-BILD) and the COPD assessment test (CAT) questionnaires.

Expected results: This study seeks to explore the synergistic value of several point-of-care-tests for the detection and differential diagnosis of ILD and COPD as well as estimate severity to better guide care management in adults

03

Conditions studied

  • Lung; Disease, Interstitial, With Fibrosis
  • Pulmonary Disease, Chronic Obstructive
  • Artificial Intelligence

Keywords

  • Lung; Disease, Interstitial, with Fibrosis
  • Idiopathic Pulmonary Fibrosis
  • Idiopathic Interstitial Pneumonias
  • Pulmonary Disease, Chronic Obstructive
  • Artificial Intelligence
  • Deep Learning
  • Respiratory Sounds; Auscultation
  • Ultrasonography
  • Diagnostic imaging
04

In context

Pulmonary Disease, Chronic Obstructive Reclassified

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

This study's planned enrollment of 160 is close to the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Pediatric Clinical Research Platform is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cases: 120 patients (80 ILD [40 IPF, 40 NSIP], 40 COPD) will be recruited from an outpatient pulmonology clinic in Switzerland in daily clinical practice on the day of intervention.

Probable and definitive IPF diagnosis will be made according to the Fleischner Society Consensus, NSIP diagnosis with the American Thoracic Society classification, and COPD with the Global Initiative for Chronic Obstructive Lung Disease criteria.

Controls: 40 age-matched (+/- 2.5 years) never smokers with normal lung function (spirometry, lung volume and transfer factor for carbon monoxide) followed in the pulmonology outpatient clinic with similar quality of electronic medical records but for diseases other than the outcome of interest (see eligibility criteria) will serve as the 1:1 control group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • age > 18 years old.
  • patients with already-diagnosed IPF (group 1) prior to the consultation (index) date.
  • patients with already-diagnosed NSIP (group 2) prior to the consultation (index) date.
  • patients with already-diagnosed (group 3) prior to the consultation (index) date.
  • Control subjects must be followed-up at the pulmonology outpatient clinic for:

    1. obstructive sleep apnoea.
    2. occupational lung diseases (miners, chemical workers, etc.).
    3. pulmonary nodules (considered benign after 2 years).

Exclusion criteria

Exclusion Criteria:

  • patients who cannot be mobilized for posterior auscultation.
  • patients known for severe cardiovascular disease with pulmonary repercussion.
  • patients known for a concurrent, acute, infectious pulmonary disease (e.g., pneumonia, bronchitis).
  • patients known for asthma.
  • patients known or suspected of immunodeficiency, alpha-1-antitrypsin deficit, and or under immunotherapy.
  • patients with physical inability to follow procedures.
  • patients with inability to give .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • IPF patients (group 1)

    Consenting adult patients \>18 years old with with already-diagnosed IPF

    Device: Lung auscultation · Device: Lung ultrasound · Other: Quality of Life's questionnaires · Diagnostic Test: Pulmonary functional tests

  • NSIP patients (group 2)

    Consenting adult patients \>18 years old with with already-diagnosed non-specific interstitial pneumonia (NSIP)

    Device: Lung auscultation · Device: Lung ultrasound · Other: Quality of Life's questionnaires · Diagnostic Test: Pulmonary functional tests

  • COPD patients (group 3)

    Consenting adult patients \>18 years old with with already-diagnosed chronic obstructive pulmonary disease (COPD)

    Device: Lung auscultation · Device: Lung ultrasound · Other: Quality of Life's questionnaires · Diagnostic Test: Pulmonary functional tests

  • Control subjects (group 4)

    Consenting age-matched (+/- 2.5 years) never smokers patients with normal lung function (spirometry, lung volume and Transfer Factor for Carbon Monoxide (TLCO)) followed in the pulmonology outpatient clinic with similar quality of electronic medical records but for diseases other than the outcome of interest, namely: 1. patients with obstructive sleep apnea. 2. patients followed-up for occupational lung diseases (miners, chemical workers, etc.). 3. patients followed-up for pulmonary nodules (considered benign after 2 years).

    Device: Lung auscultation · Device: Lung ultrasound · Other: Quality of Life's questionnaires · Diagnostic Test: Pulmonary functional tests

Interventions

  • DeviceLung auscultation

    Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).

  • DeviceLung ultrasound

    Lung ultrasonography

  • OtherQuality of Life's questionnaires

    Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)

  • Diagnostic testPulmonary functional tests

    Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.

07

What researchers measure

Primary outcomes

  1. To differentiate ILD from control subjects based on digital lung sounds recordings and LUS.

    To determine the predictive performance of the AI algorithm-evaluated lung auscultation and LUS in the identification and risk stratification of ILD signatures from control subjects described in terms of descriptive statistics, area under the receiver operating characteristic curve, sensitivity, specificity, positive and negative predictive values, and likelihood ratios (95% confidence intervals). Digital lung sounds will be transformed to Mel Frequency Cepstrum Coefficients. Several data augmentation techniques will be explored. The effect of each pre-processing method will be tested. The best performing approach according to sensitivity and specificity will be reported. This dataset will then be fed into a various deep learning networks with aggregation strategies for binary classification into positive vs negative for diagnostic results for: * ILD or control subjects * ILD or COPD * (If ILD+) IPF or NSIP The same prediction will also be made using LUS images.

    Time frame: During lung auscultation (10 minutes). Each patient will provide 10 recordings of 30 seconds. LUS images and 5 second video clips of each anatomic region (10 regions represented).

  2. Predictive performance of the DeepBreath algorithm to stratify ILD severity based on human digital lung sounds recordings and LUS (i.e. physiological parameters) compared to grading scales.

    To determine the ILD clinical severity predictive performance of the DeepBreath algorithm based on human digital lung sounds recordings and LUS, risk stratification will use multiclass or regression according to grading scales obtained from: * K-BILD and CAT impact of life questionnaire. * Lung function tests (Forced Expiratory Volume in 1 sec, Forced vital capacity, Forced Expiratory Volume in 1 sec/Forced vital capacity, Total lung capacity, functional respiratory capacity, Transfer capacity for carbon monoxide, Alveolar Volume). * High-Resolution Computed Tomography (severity markers that will be used are: traction bronchiectasis, presence of honeycombing, ground glass opacities, reticulation, emphysema. Chest CT-scans will be reviewed independently by two radiologists blinded to each other).

    Time frame: During lung auscultation (10 minutes). Each patient will provide 10 recordings of 30 seconds. LUS images and 5 second video clips of each anatomic region (10 regions represented).

  3. Performance of the DeepBreath algorithm to subcategorize ILD by discriminating digital lung sounds recordings and LUS (i.e. physiological parameters).

    The performance of the DeepBreath algorithm to determine the subcategories of ILD such as IPF and NSIP based on digital lungs sounds and LUS according to gold standard diagnosis: * IPF follows the Fleischner Society Consensus criteria. * NSIP diagnosis follows the American Thoracic Society classification.

    Time frame: During lung auscultation (10 minutes). Each patient will provide 10 recordings of 30 seconds. LUS images and 5 second video clips of each anatomic region (10 regions represented).

Secondary outcomes

  1. Performance of human expert-identified acoustic signatures.

    Comparison of the predictive performance of human expert-identified acoustic signatures in the predictive tasks described above in the primary outcomes (Kappa coefficient).

    Time frame: During the data analysis period (i.e., after the 60-minute study intervention period).

  2. Agreement of human labels with objectively clustered pathological sounds by machine learning.

    To quantify the agreement of human labels with objectively clustered pathological sounds by machine learning (ie, the DeepBreath AI algorithm).

    Time frame: During the data analysis period (i.e., after the 60-minute study intervention period).

  3. Diagnostic performance of DeepBreath to detect crackles in IPF patients.

    Diagnostic performance of the AI algorithm (DeepBreath) trained to detect crackles in IPF patients.

    Time frame: During the data analysis period (i.e., after the 60-minute study intervention period).

  4. To test whether performance of DeepBreath could be improved using clinical features (i.e., signs, respiratory symptoms, demographics, medical history and basic paraclinical tests).

    To explore the utility of adding clinical data collected at enrolment including demographic information (age and sex), several binary clinical symptoms (respiratory symptoms), medical history and basic paraclinical tests to improve the accuracy of the DeepBreath algorithm in detecting IPF from control subjects or COPD. Clinical data will be explored for their predictive capacity in the above tasks and added to the breath sound analysis either as an Support vector machine or in conditional feature extraction upstream of the neural network.

    Time frame: During the data analysis period (i.e., after the 60-minute study intervention period)

  5. K-BILD

    King's brief Interstitial Lung Disease Health Status: the K-BILD health status questionnaire is a 15 item validated, self-completed heath status questionnaire. It has three domains: breathlessness and activities, psychological and chest symptoms. The K-BILD domain and total score ranges are 0-100, with the higher scores corresponding with better health-related quality of life. This questionnaire will be used to assess the Impact of ILD on subjects' health-related quality of life. It will take about 3 minutes to complete this questionnaire.

    Time frame: Baseline

  6. CAT

    COPD assessment test: the CAT health status questionnaire is a 8 item validated, self-completed heath status questionnaire. The total CAT score ranges from 0 to 40 where 0 represents no symptoms and 40 very bad symptoms. This questionnaire will be used to assess the Impact of COPD on subjects' health-related quality of life. It will take about 3 minutes to complete this questionnaire.

    Time frame: Baseline

08

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier du Valais Romand
    Sion, Wallis 1951, Switzerland
    Recruiting
    • Pierre-Olivier Bridevaux, Prof · Contactpierre-olivier.bridevaux@hopitalvs.ch · +41276034678
    • Johan N. Siebert, MD · ContactJohan.Siebert@hcuge.ch · +41795534072
    • Pierre-Olivier Bridevaux, Prof. · Principal investigator
    • Mary-Anne Hartley, MD, PhD · Sub investigator
    • Delphine S. Courvoisier, Prof. · Sub investigator
    • Constance Barazzone-Argiroffo, Prof. · Sub investigator
    • Marlène Salamin, RN · Sub investigator
    • Alain Gervaix, Prof. · Sub investigator
    • Johan N. Siebert, MD · Sub investigator
09

References and documents

Individual participant data

Plan to share: Yes — All pertinent data generated or analysed during this study will be included in the published articles (and supplementary information files). An anonymous copy of the final (anonymized) datasets (but not digitized lung sounds) used and/or analyzed during the current study will be available from the corresponding author (see access criteria).

Supporting information: Study protocol, Clinical study report

Time frame: Data will be available beginning 6 months and ending 5 years following article publication.

Access criteria: De-identified data will be available from the corresponding author on reasonable request upon approval of a proposal and with a signed data access agreement. Data will be made available for a specified research purpose to qualified external researchers whose proposed use of the data has been approved by their institutional review board. The request proposal must include a statistician. There are no plans to share the digitized lung sounds collected during the study procedure.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Oct 2024, 18 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 18 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2022
First posted
Apr 8, 2022
StartActual
Apr 1, 2023
Primary completionEst.
Oct 6, 2024
CompletionEst.
Oct 31, 2024
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05318599
Lead sponsor
Pediatric Clinical Research Platform
Responsible party
Sponsor
First posted
Apr 8, 2022
Start date
Apr 1, 2023
Primary completion
Oct 6, 2024 (estimated)
Completion
Oct 31, 2024 (estimated)
Last update
Apr 12, 2024

Study contacts

Johan N. Siebert, MD
Contact
Johan.Siebert@hcuge.ch
+41795534072
Pierre-Olivier Bridevaux, Prof.
Contact
pierre-olivier.bridevaux@hopitalvs.ch
+41276034678
Pierre-Olivier Bridevaux, Prof.
principal investigator · Hôpital du Valais, Switzerland
Johan N. Siebert, MD
study director · Geneva University Hospitals, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion